BioCryst Pharmaceuticals Inc. (BCRX) Trading 2.3% Higher
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) traded up 2.3% during trading on Monday . The company traded as high as $4.57 and last traded at $4.43, with a volume of 355,054 shares trading hands. The stock had previously closed at $4.33.
A number of brokerages have issued reports on BCRX. Piper Jaffray Cos. upgraded BioCryst Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $5.00 to $8.00 in a research note on Friday, August 12th. HC Wainwright restated a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Friday, August 5th. JPMorgan Chase & Co. restated a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Friday, August 5th. Jefferies Group upped their price objective on BioCryst Pharmaceuticals from $2.00 to $3.00 and gave the company a “hold” rating in a research note on Friday, August 5th. Finally, JMP Securities downgraded BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 4th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $8.22.
The company’s market cap is $350.81 million. The stock has a 50 day moving average price of $3.70 and a 200 day moving average price of $3.07.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.04. During the same quarter in the previous year, the firm posted $0.06 EPS. The company had revenue of $4.80 million for the quarter, compared to analysts’ expectations of $3.92 million. The firm’s quarterly revenue was down 81.4% compared to the same quarter last year. Equities analysts expect that BioCryst Pharmaceuticals Inc. will post ($1.03) earnings per share for the current fiscal year.
In other BioCryst Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker sold 4,046,590 shares of BioCryst Pharmaceuticals stock in a transaction on Tuesday, August 16th. The stock was sold at an average price of $5.00, for a total transaction of $20,232,950.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Thomas R. Staab II sold 5,864 shares of BioCryst Pharmaceuticals stock in a transaction on Friday, August 12th. The shares were sold at an average price of $5.18, for a total value of $30,375.52. Following the transaction, the insider now owns 128,745 shares of the company’s stock, valued at approximately $666,899.10. The disclosure for this sale can be found here.
An institutional investor recently raised its position in BioCryst Pharmaceuticals stock. Morgan Stanley increased its position in shares of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) by 13.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 103,804 shares of the biotechnology company’s stock after buying an additional 12,646 shares during the period. Morgan Stanley owned about 0.14% of BioCryst Pharmaceuticals worth $1,071,000 at the end of the most recent reporting period.
BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.